Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Rhabdomyosarcoma × Ifosfamide × Clear all

Phase

Phase 3 5 Phase 2 3 Phase NA 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 7 Hodgkin Disease 7 Lymphoma, Follicular 5 Lymphoma 5 Testicular Neoplasms 4 Testicular Germ Cell Tumor 4 Sarcoma 4 Ovarian Neoplasms 4 Osteosarcoma 4 Lymphoma, Non-Hodgkin 4 Lymphoma, Mantle-Cell 4 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, Large-Cell, Anaplastic 3 Burkitt Lymphoma 3 Waldenstrom Macroglobulinemia 2 Solitary Fibrous Tumors 2 Small Cell Lung Carcinoma 2 Sarcoma, Clear Cell 2 Recurrence 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms 2 Lymphoma, B-Cell, Marginal Zone 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Immunoblastic Lymphadenopathy 2 Hemangiosarcoma 2 Hemangioendothelioma, Epithelioid 2 Chondrosarcoma, Extraskeletal Myxoid 2 Central Nervous System Neoplasms 2 Vascular Neoplasms 1 Urinary Bladder Neoplasms 1

Interventions

Temozolomide 6 Irinotecan 6 Vincristine 4 Nivolumab 2 temsirolimus 1 talazoparib 1 surufatinib 1 silmitasertib 1 regorafenib 1 prexasertib 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 liposomal doxorubicin 1 lenvatinib 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 irinotecan sucrosofate 1 ganitumab 1 eribulin 1 efineptakin alfa 1 dostarlimab 1 dinutuximab 1 copanlisib 1 bempegaldesleukin 1 adavosertib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Thrombopoietin 1 Receptor Protein-Tyrosine Kinases 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04625907 2024-05-23

FaR-RMS

University of Birmingham

Phase 1/2 Recruiting

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡